Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Europe's drugs regulator said on Friday it had launched a real-time review of CureVac's (5CV.DE), COVID-19 vaccine to speed ...

When all is done, Vaxart could get more money in this new deal than it was set to get under its Health and Human Services ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States—sending greater numbers of babies and toddlers to the hospital, recent data show.

GlaxoSmithKline Inc. was registered by Chase Tribble, a consultant with Counsel Public Affairs Inc. for a number of lobbying ...

BioIndustry Association welcomes new Board Chair. The BioIndustry Association, which supports biotech innovation in the UK, ...

Trade flows remain balanced at roughly $48 billion in imports and $49 billion in exports, yet 91% of biologics sold domestically are imported, revealing a paradox: America manufactures heavily but ...

RSV is the leading cause of infant hospitalization in the U.S.• Health officials urge vaccination for pregnant women, seniors ...